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Background: Due	 to	 important	 biases,	 conventional	 end-	of-	day	 and	 end-	of-	week	











gastrointestinal	 symptoms	were	 significantly	 associated	 (ICCs	 range	 0.770–	0.917).	
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1  |  INTRODUC TION
Functional	dyspepsia	(FD)	 is	one	of	the	most	common	functional	
gastrointestinal disorders, recently renamed in disorders of gut- 
brain	 interaction,	 with	 an	 estimated	 prevalence	 of	 10%–	15%	 in	
the general population.1	 According	 to	 the	 Rome	 IV	 criteria	 for	
functional gastroduodenal disorders, it is defined by the pres-
ence of various symptoms in the absence of organic, systemic, 
or	 metabolic	 diseases	 that	 could	 explain	 complaints.2	 Among	
the	 heterogeneous	 presentation	 of	 patients	 with	 FD,	 four	 core	
symptoms have been defined: early satiation, postprandial full-
ness, epigastric burning, and epigastric pain.2,3 Quality of life and 
work	 productivity	 are	 impaired	 in	 patients	 with	 FD.4	Moreover,	
up to 40% of patients will consult a physician, having substantial 
financial implications.5	The	diagnosis	of	FD	largely	relies	on	symp-
toms, since underlying pathophysiologic mechanisms remain un-
clear	and	specific	biological	markers	are	currently	lacking.	Hence,	
symptom assessment is warranted to evaluate treatment efficacy. 
The	 Food	 and	 Drug	 Administration	 (FDA)	 recommends	 the	 use	
of	well-	defined	patient-	reported	outcome	measures	(PROMs)	for	
evaluation of treatment outcomes in clinical trials.6	A	recent	sys-
tematic	 review	 identified	 20	 PROMs	 for	 assessment	 of	 dyspep-
tic symptoms. However, no single instrument has undergone all 
the	development	steps	recommended	by	the	FDA.	Therefore,	no	
consensus has yet been reached with regard to the most relevant 
outcome	measure	in	patients	with	FD.7
The	currently	used	assessment	methods	 to	evaluate	dyspep-
tic symptoms and response to treatment are mainly retrospective, 
self-	reported	 questionnaires,	 based	 on	 daily	 or	weekly	monitor-
ing.	This	has	important	limitations.	Firstly,	retrospective	question-
naires are prone to recall bias.8	Secondly,	 symptom	variability	 in	
functional	 disorders	 can	 occur	 due	 to	 external	 triggers,	 such	 as	
intake	of	food	or	psychological	factors,9–	11 which cannot be accu-
rately captured by retrospective assessments, thereby resulting in 
ecological	bias.	Thirdly,	 lack	of	patient	adherence	or	 fake	adher-
ence	is	common	problems	that	arise	with	the	use	of	paper	ques-
tionnaires.12	 These	 limitations	 underline	 the	 need	 for	 a	 reliable	





completed	within	 a	 short	 time	 after	 an	 auditory	 signal,	 and	 ques-
tions	 always	 relate	 to	 current	 symptoms,	 contextual	 factors,	 and	
psychological	factors.	Therefore,	ESM	might	be	able	to	reduce	the	
risk	 of	 recall	 and	 ecological	 bias	 and	 capture	 symptom	 variability	
However,	end-	of-	day	scores	were	significantly	higher	(Δ0.329–	1.031)	than	mean	ESM	
scores	(p	<	0.05).	Comparing	ESM	with	NDI	and	PAGI-	SYM	scores,	correlations	were	
weaker	(Pearson's	r	range	0.467–	0.846).	Cronbach's	α coefficient was good for upper 
gastrointestinal	symptoms	(α	=	0.842).	First	half-	week	and	second	half-	week	scores	
showed	very	good	consistency	(ICCs	range	0.913–	0.975).
Conclusion and Inferences: Good	validity	and	reliability	of	a	novel	ESM-	based	PROM	
for	assessing	gastrointestinal	symptoms	in	FD	patients	was	demonstrated.	Moreover,	
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over time.13,14	 Current	 use	 of	 ESM	 in	 gastrointestinal	 disorders	 is	
limited.	Several	 studies	evaluated	 the	use	of	ESM	 in	patients	with	
irritable	 bowel	 syndrome	 (IBS)	 and	 found	 good	 correlation	 be-
tween	 symptom	scores	on	ESM	and	 retrospective	questionnaires.	
However, abdominal pain scores were significantly higher in retro-
spective	questionnaires	 compared	with	mean	scores	derived	 from	
ESM.	Interestingly,	the	scores	for	abdominal	pain	on	retrospective	








the	Netherlands	 (ID	METC19-	077),	 and	 performed	 in	 full	 accord-
ance	 with	 the	 Declaration	 of	 Helsinki	 (latest	 amendment	 by	 the	
World	Medic	Association	in	2013)	and	Dutch	Regulations	of	Medical	
Research	 involving	 Human	 Subjects	 (WMO,	 1998).	 This	 prospec-
tive	observational	study	was	performed	at	the	MUMC+	from	May	
29,	 2020,	 until	October	1,	 2020.	This	 study	was	 registered	 in	 the	








(NCT02522000,	 NCT03652571).	 Functional	 dyspepsia,	 including	
subtype	assessment,	was	diagnosed	according	to	the	Rome	IV	crite-







an uncomfortable feeling of early satiation that resulted in inability 
to	finish	a	normal-	sized	meal	for	at	least	3	days	or	more	per	week	







were the initiation of regularly used medication from 1 month be-
fore inclusion until the end of the study period, a history of upper 
gastrointestinal surgery, history of radiation therapy to the abdo-
men,	and	pregnancy.	Subjects	could	only	participate	if	they	under-
stood the Dutch language and were able to use the smartphone 




2.2  |  Data collection
Experience	 sampling	 method	 and	 an	 end-	of-	day	 symptom	 diary	
were collected during seven consecutive days. On day 7, subjects 








as often as possible, subjects were instructed to carry their smart-
phone	with	them	during	the	week.	The	MEASuRE-	D	application	sent	
out a haptic, auditory, and written signal 10 times per day between 




repeated in the same order, and scored on an 11- point numeric rating 
scale	(NRS)	(0	=	not	at	all	to	10	=	very	severely).	The	development	of	
this	ESM-	based	questionnaire	has	been	described	previously.18
2.4  |  End- of- day diary
A	7-	day	end-	of-	day	symptom	diary	was	used	to	evaluate	symptom	
severity	on	a	daily	basis.	Gastrointestinal	symptoms	(i.e.,	upper	ab-
dominal fullness, upper abdominal heaviness, bloating, upper ab-
dominal pain, upper abdominal burning sensation, lower abdominal 
pain, nausea, belching, heartburn, regurgitation, ability to eat nor-
mal	portion	sizes,	vomiting,	and	urge	to	defecate)	were	scored	using	
an	11-	point	NRS	(0	=	not	at	all	to	10	=	very	severely)	at	the	end	of	
each	 test	day.	This	 symptom	diary	was	built	 into	 the	MEASuRE-	D	
application	and	made	available	between	19:00	and	0:00.	Subjects	
were instructed to manually open the application to fulfill this 
diary, as no signal was sent to the smartphone to indicate avail-
ability	of	 this	questionnaire.	 In	 the	application,	 this	 list	was	 called	
‘Avondvragenlijst’	(Figure	S1).
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2.5  |  End- of- week questionnaires
At	the	end	of	the	study	period,	validated	questionnaires	were	com-
pleted	 using	 an	 eCRF,	 assessing	 upper	 gastrointestinal	 symptoms	
and mental health status. Regarding upper gastrointestinal symptom 
severity,	 the	 Nepean	 Dyspepsia	 Index	 (NDI;	 0–	4	 scale	 for	 occur-
rence	of	core	complaints,	0–	5	scale	for	severity	of	core	complaints,	
0–	4	 scale	 for	 hinderance	 due	 to	 core	 complaints,	 recall	 period	
14	days)24–	26	and	Patient	Assessment	of	Gastrointestinal	Symptom	
Severity	 Index	 (PAGI-	SYM;	 1–	6	 scale;	 composes	 subscores	 for	
postprandial fullness, nausea/vomiting, bloating, upper abdominal 
pain, lower abdominal pain, heartburn/regurgitation, recall period 
14	days)27 were completed.
The	 Generalized	 Anxiety	 Disorder	 Scale-	7	 (GAD-	7;	 0–	3	 scale;	
total	composite	score	for	severity	of	anxiety	symptoms;	recall	period	






2.6  |  Statistical analyses
Sample	size	was	based	on	previous	studies	using	ESM	data	that	have	
shown	 sample	 sizes	 between	 20	 and	 30	 subjects	 to	 be	 sufficient	








outcomes	 are	 presented	 as	 mean	 ±	 standard	 deviation	 (SD)	 and	
tested using paired or independent samples t- test. Proportions for 
categorical variables were tested using the χ2-	test.	For	all	analyses,	





calculated	 for	 each	 of	 the	 7	 days.	 Associations	 between	 ESM	
scores	 and	 end-	of-	day	 scores	were	 tested	 using	 a	 linear	mixed-	
effects	model	with	end-	of-	day	score	as	 the	dependent	and	ESM	
score as the independent variable, a random intercept, and cor-
recting	 for	 repeated	measures	 by	 using	 an	 autoregression	 (AR1)	
correlation	 structure.	 The	 level	 of	 agreement	 between	 these	




as the dependent variable were used to assess differences be-
tween assessment methods.
In	order	 to	compare	ESM	scores	with	end-	of-	week	question-
naire	 scores,	 average	 ESM	 scores	 were	 calculated	 per	 subject.	
Paired samples t- test and Pearson correlations were calculated to 
assess	the	differences	between	measurement	methods.	A	Pearson	
r above 0.7 reflects a strong correlation, a Pearson r	of	0.50–	0.70	
reflects a good correlation, a Pearson r between 0.3 and 0.5 re-
flects a moderate correlation, and a Pearson r below 0.30 reflects 
a poor correlation.37	 For	 the	 PAGI-	SYM	 questionnaire,	 the	 sub-
scores for postprandial fullness, nausea/vomiting, bloating, upper 
abdominal pain, lower abdominal pain, and heartburn/regurgita-
tion	were	used.	Corresponding	ESM	scores	that	were	used	were	







Reliability was assessed with the internal consistency and 
test-	retest	 reliability.	 For	 assessment	 of	 internal	 consistency	 with	
Cronbach's	α	 coefficient,	 the	ESM-	PROM	 items	were	divided	 into	
five	 domains	 (i.e.,	 upper	 gastrointestinal	 symptoms,	 lower	 gastro-







symptom, mean scores were calculated per subject for these two 
time	periods.	A	paired	samples	t- test was performed to test the dif-









did	not	 complete	at	 least	1/3	of	 the	 total	number	of	ESM	assess-
ments.	 Therefore,	 35	 patients	 (25	 female	 [71.4%],	 age	 44.7	 [SD	
15.7]	years,	GAD-	7	4.8	[SD	4.5],	HADS-	Anxiety	5.3	[SD	4.5],	HADS-	
Depression	4.9	[SD	4.3])	were	included	in	the	analyses.	Ten	patients	
fulfilled	 the	 criteria	 for	EPS	 (28.6%),	 seven	 for	PDS	 (20%),	 and	18	
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3.2  |  Compliance
The	completion	 rate	of	ESM	assessments	was	62.2%.	Over	 the	7-	
day period, a mean number of 43.5 measurements was completed 
per	 individual	 (range:	 23–	68).	 The	majority	 of	 subjects	 completed	
between	31	and	60	assessments	during	the	study	period	(Figure	1).
3.3  |  Concurrent validity
3.3.1  |  ESM	scores	compared	with	end-	of-	day	
diary scores
Both	 ESM	 and	 the	 end-	of-	day	 diary	 scored	 the	 following	 gastro-
intestinal symptoms: upper abdominal fullness, upper abdominal 
heaviness, bloating, upper abdominal pain, upper abdominal burning 
sensation, lower abdominal pain, nausea, belching, heartburn, and 
regurgitation.
Mean	 scores	 on	 ESM	 and	 end-	of-	day	 scores	 were	 all	 signifi-
cantly associated, which indicates that both assessment methods 
measure	the	same	construct	(Table	1).	Furthermore,	ICCs	between	
F I G U R E  1 Number	of	individuals	(y-	axis)	per	category	of	
completed	number	of	assessments	(x-	axis)
23−30 31−40 41−50 51−60 61−70























Estimate SE ICC 95%- CI
Fullness 0.952*** 0.084 0.790 0.729–	0.839
Heaviness 1.025*** 0.060 0.803 0.745–	0.849












1.103*** 0.078 0.770 0.703–	0.823
Nausea 1.147*** 0.052 0.872 0.832–	0.903
Belching 1.045*** 0.061 0.861 0.818–	0.894
Heartburn 1.107*** 0.043 0.917 0.891–	0.938









TA B L E  2 Difference	between	ESM	mean	and	maximum	scores	
and end- of- day diary scores
Symptom
ESM mean versus 
end- of- day
ESM maximum versus 
end- of day
Difference SE Difference SE
Fullness 1.031*** 0.191 −1.001*** 0.233
Heaviness 0.875*** 0.127 −1.133*** 0.164












0.562*** 0.151 −0.459*** 0.120
Nausea 0.524*** 0.128 −0.597*** 0.113
Belching 0.677*** 0.150 −0.387*** 0.115
Heartburn 0.459*** 0.125 −0.398*** 0.103
Regurgitation 0.329* 0.131 −0.359*** 0.080
Note: A	positive	difference	indicates	a	higher	score,	and	a	negative	





is depicted by estimate.
Abbreviation:	SE,	Standard	error.
*p < 0.05.; **p < 0.01.; ***p < 0.001.
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ESM	scores	and	end-	of-	day	diary	scores	were	all	above	0.75,	indicat-
ing	good	agreement	between	these	assessment	methods	(Table	1).	
However, symptom scores were all significantly higher in end- of- day 
diaries	 compared	 with	 mean	 ESM	 scores	 (Table	 2).	 Furthermore,	
symptom scores were all significantly lower in end- of- day diaries 
compared	with	maximum	ESM	scores.	Therefore,	end-	of-	day	diary	
scores	were	placed	in	between	the	mean	and	maximum	ESM	scores	
for	 all	 gastrointestinal	 symptoms.	 This	 concept	 is	 illustrated	 in	
Figure	2	for	fullness	scores.





patient	 reported	 multiple	 time-	points	 without	 fullness	 (i.e.,	 score	
0)	or	with	 low	feelings	of	 fullness	 (i.e.,	 scores	below	5)	and	only	a	
few	time-	points	with	higher	symptom	scores	(i.e.,	above	5).	Instead	
of real- time symptom assessment, end- of- day diary scores reflect 
scores	of	the	entire	day.	For	this	individual,	this	resulted	in	end-	of-	
day	fullness	scores	higher	than	5	for	6	out	of	7	days.	Figure	3	high-




week	 scores	are	depicted	 in	Table	3.	ESM	scores	 for	postprandial	
fullness, nausea, bloating, upper abdominal pain, lower abdominal 
pain, heartburn, upper abdominal burning, and belching were all 
lower	compared	with	end-	of-	week	scores	on	the	NDI	and	PAGI-	SYM.	
Scores	for	upper	abdominal	burning,	heartburn,	bloating,	and	belch-





F I G U R E  2 Daily	fullness	scores	based	





as the dependent variable, corrected 
for	repeated	measures	(AR1	covariate	
structure)	were	used	to	test	significance
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strongly	correlated	with	ESM	scores.	All	other	PAGI-	SYM	subscores	
showed	good	correlation	with	ESM	scores.
In addition to gastrointestinal symptoms, psychological fac-
tors	were	assessed	with	ESM.	Several	psychological	factors	corre-
sponded	with	the	PHQ-	9	or	GAD-	7,	namely	‘feeling	down’,	 ‘feeling	
anxious’,	 ‘feeling	 worried’,	 ‘feeling	 irritated’,	 and	 ‘feeling	 relaxed’.	
Answering	scales	were	substantially	different	and,	therefore,	did	not	
allow	for	harmonization	of	the	scores.	Hence,	no	mean	scores	could	
be compared between assessment methods. However, correlations 
between	the	two	assessment	methods	could	be	calculated.	Strong	
correlations	between	ESM	and	end-	of	week	scores	were	found	for	
‘feeling	 down’,	 ‘feeling	 worried’,	 ‘feeling	 irritated’,	 and	 ‘feeling	 re-
laxed’.	Good	correlations	were	found	for	‘feeling	anxious’.
3.4  |  Internal consistency
Internal	 consistency	 of	 the	 ESM-	PROM	 for	 FD	 was	 deter-
mined	 by	 categorizing	 the	 items	 in	 five	 constructs,	 namely	 upper	
gastrointestinal symptoms, lower gastrointestinal symptoms, physi-
cal non- gastrointestinal symptoms, positive affect, and negative 
affect.	Table	4	lists	Cronbach's	α coefficients for these constructs. 
Very	good	 internal	consistency	was	 found	for	upper	gastrointesti-
nal symptoms and negative affect. Good internal consistency was 
found	 for	 physical	 non-	gastrointestinal	 symptoms.	 An	 acceptable	
internal	consistency	was	found	for	positive	affect.	Consistency	was	
relatively low for lower gastrointestinal symptoms, indicating that 
these two symptoms might not perfectly reflect the same construct 
for lower gastrointestinal symptoms.











Mean ± SD Pearson correlation
Upper	abdominal	pain 1.88 ± 2.05 3.72	±	2.29*** 0.617
Upper	abdominal	burning 1.37 ± 2.01 2.10 ± 2.56** 0.846
Heartburn 1.35	±	1.96 2.51 ± 2.71*** 0.737
Reflux 0.58 ± 1.05 1.94	±	2.39*** 0.465
Fullness 2.88	±	1.98 4.66 ± 2.24*** 0.574
Bloating 2.86	±	1.95 4.03 ± 2.84*** 0.838
Nausea 1.35	±	1.91 3.25 ± 2.85*** 0.556
Belching 1.23 ± 1.63 2.67	±	2.79*** 0.779
PAGI- SYM versus ESM
PAGI- SYM subscale score
Mean ± SD
Postprandial fullness 2.88	±	1.98 3.89	±	2.06** 0.636
Nausea/vomiting 1.35	±	1.91 1.64 ± 2.05 0.556
Bloating 2.86	±	1.95 4.64	±	2.89*** 0.728
Upper	abdominal	pain 1.81 ± 2.05 3.75 ± 2.44*** 0.804
Lower	abdominal	pain 1.16 ± 1.56 2.20	±	2.29*** 0.680
Heartburn/regurgitation 1.35	±	1.96 1.92	±	1.87** 0.802












satiety and fullness, nausea/vomiting and nausea, bloating and bloating, upper abdominal pain and upper abdominal pain, lower abdominal pain and 
lower	abdominal	pain,	heartburn/regurgitation	and	heartburn.	PHQ-	9/GAD-	7	versus	ESM:	answering	scales	do	not	allow	comparison	between	mean	
scores. Paired samples t- test was used to test for differences.
**p < 0.01.; ***p < 0.001.
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first	 half-	week	 and	 the	 second	 half-	week.	 All	 symptoms	 showed	





velopment of this tool has been previously described.18	This	study	
demonstrated	 significant	 associations	 between	 ESM	 scores	 for	
gastrointestinal symptoms and end- of- day scores, and moderate- to- 
strong	 correlations	between	ESM	 scores	 and	 end-	of-	week	 scores,	
confirming concurrent validity. Besides validity, reliability was con-
sidered	adequate	based	on	moderate-	to-	good	 internal	consistency	
and	excellent	test-	retest	reliability.
Prior	 to	 the	 implementation	 of	 a	 novel	 PROM	 in	 patient	
care	 or	 clinical	 trials,	 adequate	 validity	 and	 reliability	 have	 to	 be	
demonstrated.	Throughout	the	years,	a	plethora	of	statistical	meth-
ods	to	test	psychometric	properties	of	novel	PROMs	have	been	de-
scribed.6,38,40 In this study, measures of validity and reliability that are 
most	applicable	to	the	novel	ESM-	based	PROM	are	used.	Regarding	
concurrent	 validity,	 significant	 associations	 for	 all	 mean	 ESM	 and	
end- of- day scores for gastrointestinal symptoms were found. Given 
the good agreement between these assessment methods, it can be 
stated	 that	 the	 ESM-	PROM	and	 end-	of-	day	 diary	measure	 similar	




ESM	 scores.	 This	 points	 toward	 over-	reporting	 of	 gastrointestinal	
complaints when subjects need to provide one score over the en-
tire	day.	The	difference	between	mean	ESM	scores	and	end-	of-	week	
scores	was	even	more	pronounced.	This	indicates	that	subjects	tend	
to remember the moments that they were aware of complaints and 
neglect the moments without complaints when providing scores 
over	a	longer	period	of	time,	emphasizing	the	usefulness	of	ESM	in	
generating accurate individual symptom patterns.
This	 study	 demonstrated	 very	 good	 internal	 consistency	 for	
upper gastrointestinal symptoms, whereas a poor consistency was 
found	 for	 lower	gastrointestinal	 symptoms.	This	 suggests	 that	 the	
two	items	chosen	to	represent	lower	gastrointestinal	symptoms	(i.e.,	
bloating	and	lower	abdominal	pain)	should	possibly	be	considered	to	
reflect different constructs. It should be noted that the items were 
selected	based	on	focus	group	interviews	with	FD	patients.	A	pre-
vious	study	developed	an	ESM-	based	PROM	for	 IBS	patients	 that	
included more items reflecting lower gastrointestinal symptoms.33 
It	could	have	been	possible	to	combine	both	PROMs.	However,	this	
would have increased the number of total symptom items substan-
tially	 and,	 therefore,	 the	 patient's	 burden.	 Instead,	we	 decided	 to	
focus	on	 the	 symptoms	deemed	essential	 by	 patients	with	 FD,	 as	
reflected by the item selection in the focus groups. However, inter-
nal	 consistency	might	 have	 been	 improved	 by	 expanding	 this	 do-
main with lower gastrointestinal symptoms that are deemed more 
appropriate.






symptoms	and	the	 influence	of	subjects'	daily	 life	on	 (gastrointesti-
















































end- of- day reporting, as multiple assessments during the day are 
likely	 to	 be	more	 time-	consuming	 than	most	 conventional	 assess-
ment	methods.	The	accuracy	of	the	assessment	method	would	be	at	
stake	if	this	had	resulted	in	low	adherence.	A	completion	rate	of	33%	
for	ESM-	based	PROMS	is	conventionally	accepted.35,36 In the pres-
ent study, 62.2% of the total assessments was completed. Reported 
completion	rates	are	reliable	and	accurate,	since	ESM	assessments	
were only available for a set period of time and electronic date and 
timestamps were registered for each assessment.
A	particular	 strength	of	 the	present	 study	 is	 the	validation	of	
this	novel	tool	according	to	the	recommendations	of	de	FDA.6	An	
important addition is that conventionally static measures of health 
status at specific time- points are used for comparison. In contrast 
to	 end-	of-	day	 or	 end-	of-	week	 health	 questionnaires,	 ESM	 is	 able	
to detect short- term fluctuations in symptoms by its dynamic as-
sessment	 of	 symptomatology.	 Therefore,	 ESM	 has	 the	 ability	 to	
provide a more detailed and individual assessment of symptom 
patterns.	Moreover,	this	study	demonstrated	the	suitability	of	ESM	
to	provide	an	overview	of	patients'	 symptoms	over	 the	7-	day	pe-
riod and a detailed insight into within- day fluctuations of symp-
toms.	Furthermore,	by	assessing	other	symptoms	at	the	exact	same	
moments,	ESM	offers	 the	opportunity	 to	 investigate	associations	
between concurrent symptoms, environmental factors, and psy-
chological symptoms.13,42	This	means	that	ESM	is	capable	of	inves-
tigating symptom formation, in other words, how symptoms impact 
TA B L E  5 Mean	scores	for	ESM-	reported	gastrointestinal	symptoms,	non-	gastrointestinal	physical	symptoms,	and	mental	status	in	the	
first	half-	week	and	second	half-	week	of	the	study	period
First half- week
Mean score ± SD
Second half- week
Mean score ± SD ICC [95%- CI]
Gastrointestinal symptoms
Fullness 2.94	±	1.93 2.79	±	2.08 0.913	[0.828–	0.956]
Upper	abdominal	heaviness 2.58 ± 1.72 2.48	±	1.91 0.935	[0.871–	0.967]
Bloating 2.99	±	1.86 2.74 ± 2.13 0.934	[0.869–	0.966]
Upper	abdominal	pain 1.74	±	1.89 1.86 ± 2.22 0.956	[0.913–	0.978]
Upper	abdominal	burning 1.40	±	1.90 1.36 ± 2.11 0.957	[0.915–	0.978]
Lower	abdominal	pain 1.24 ± 1.57 1.13 ± 1.65 0.947	[0.896–	0.973]
Nausea 1.43 ± 2.00 1.28 ± 1.82 0.970	[0.940–	0.985]
Belching 1.27 ± 1.67 1.24 ± 1.77 0.942	[0.884–	0.971]
Heartburn 1.30 ± 1.82 1.41 ± 2.16 0.915	[0.832–	0.957]
Regurgitation 0.53 ± 1.17 0.58	±	0.96 0.931	[0.864–	0.965]
Non-	gastrointestinal	physical	symptoms
Palpitations 0.68 ± 1.33 0.67 ± 1.52 0.953	[0.907–	0.976]
Sweating 1.50	±	2.19 1.37 ± 2.27 0.958	[0.918–	0.979]
Dyspnoea 1.20	±	1.96 1.35 ± 2.12 0.975	[0.950–	0.987]
Dizziness 0.65 ± 1.34 0.67 ± 1.47 0.955	[0.910–	0.977]
Pressure on chest 0.89	±	1.62 1.06	±	1.95 0.955[0.910–	0.977]
Tired 4.77 ± 2.36 5.03 ± 2.35 0.966	[0.930–	0.983]
Mental	status
Good 6.11 ± 1.62 6.32 ± 1.50 0.931	[0.862–	0.965]
Down 1.41 ± 1.85 0.98	±	1.67** 0.929	[0.822–	0.968]
Anxious 0.85 ± 1.58 0.48 ± 1.44** 0.914	[0.804–	0.959]
Irritated 1.32	±	1.90 1.02 ± 1.80* 0.963	[0.914–	0.982]
Stressed 2.26 ± 2.27 1.79	±	2.33* 0.938	[0.858–	0.971]
Relaxed 6.15 ± 1.80 6.22 ± 1.83 0.929	[0.859–	0.964]
Worried 2.07 ± 2.61 1.66 ± 2.54* 0.941	[0.878–	0.971]
Note: Agreement	between	first	and	second	half-	week	is	reflected	by	the	ICC.	First	half-	week	reflects	day	1,	2,	and	3.	Second	half-	week	reflects	day	5,	
6, and 7. Paired samples t- test was used to test for significance.
Abbreviations:	ICC,	intraclass	correlation	coefficient;	SD,	standard	deviation.
*p < 0.05.; **p < 0.01.




even	 demonstrated	 the	 capability	 of	 ESM-	based	 self-	monitoring	
combined with positive emotion enhancement to enhance treat-
ment effects in patients treated for depression.43	This	emphasizes	
the	 capability	 of	 ESM	 to	 aid	 in	 disease	 insight,	 self-	management,	
and	improved	shared	decision	making.
Moreover,	FD	is	characterized	as	a	heterogeneous	disorder	often	
accompanied by general somatic complaints and/or psychological 
disturbances.	This	is	reflected	by	a	considerable	number	of	studies	
describing	 lower	 levels	 of	 physical	 and	mental	 quality	 of	 life.44–	48 
Therefore,	items	reflecting	frequently	reported	physical	complaints	
and mental state were included in addition to gastrointestinal symp-
toms.	Previous	studies	have	described	the	assessment	of	patients'	
mental	state	by	using	ESM-	based	PROMs.32,49,50 However, the main 




outcome measures, it has been recommended to include at least 
50 subjects.51 However, the large number of repeated measures 
per subject provides a significant increase in power, which is a 
substantial	 strength	of	ESM	concerning	 required	sample	sizes	 in	
clinical	trials.	Moreover,	 in	this	small	sample	size,	adherence	was	
reasonable. However, adherence should be evaluated in a larger 
pragmatic	trial	in	order	to	adequately	evaluate	compliance	to	the	
present	smartphone	application.	Furthermore,	potential	user	bias	
should	 be	 considered,	 as	 this	 study	 required	 subjects	 to	 own	 a	
smartphone	and	to	be	able	to	adequately	operate	the	smartphone	
application	 requiring	 sufficient	 digital	 skills.	 Additionally,	 inten-
sive recording using this smartphone application was mandatory. 
Another	 important	aspect	 in	quality	testing	of	PROMs	 is	assess-
ment	of	responsiveness	(i.e.,	the	sensitivity	to	detect	change	over	
time).38,40,52 In the present study, responsiveness was not eval-





internal consistency, and very good test- retest reliability were 
demonstrated	 for	 the	novel	ESM-	based	PROM	for	patients	with	
FD.	Moreover,	the	ESM-	based	PROM	has	the	advantage	of	eval-
uating individual symptom patterns, providing the opportunity to 
evaluate interactions between symptoms and environmental fac-
tors. It must be noted that this was not evaluated in the present 
study as the goal of the present study was merely the validation 
of	 the	used	 smartphone	application.	Future	 studies	 should	eval-
uate the potential of this tool to evaluate these interactions, as 
this may lead to increased insight into their illness and tools for 
self-	management,	 and	 improved	 shared	 decision	 making.	 Thus,	
this	novel	ESM-	based	tool	has	 the	ability	 to	aid	 in	 the	transition	
toward	more	personalized	health	care	for	patients	with	FD.	Future	
research	 for	 assessment	 of	 responsiveness	 of	 this	 novel	 ESM-	
based	PROM	is	warranted,	 in	order	to	determine	 its	place	 in	the	
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